1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Parkinson’s Disease Therapeutics Market
2.2. Global Parkinson’s Disease Therapeutics Market, By Drug Class, 2023 (US$ Million)
2.3. Global Parkinson’s Disease Therapeutics Market, By Distribution Channel, 2023 (US$ Million)
2.4. Global Parkinson’s Disease Therapeutics Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Parkinson’s Disease Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Parkinson’s Disease Therapeutics Market Vendors
3.2. Strategies Adopted by Parkinson’s Disease Therapeutics Market Vendors
3.3. Key Industry Strategies
4. Parkinson’s Disease Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Parkinson’s Disease Therapeutics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Dopamine Agonists
5.3.2. Levodopa/ Carbidopa
5.3.3. Anticholinergic Drugs
5.3.4. Monoamine Oxidase B (MAO-B) Inhibitors
5.3.5. Catechol-O-Methyltransferase (COMT) Inhibitors
5.3.6. Adenosine A2 Receptor Antagonist
5.3.7. Pipeline Candidates: Overview
5.3.7.1. Phase III (Market estimations by 2026)
5.3.7.1.1. APL-130277 (Cynapsus Therapeutics-Sunovion)
5.3.7.1.2. Accordion Pill Carbidopa/Levodopa (Intec Pharma)
5.3.7.1.3. P2B-001 (Pharma Two B)
5.3.7.1.4. ND0612H (Neuroderm)
5.3.7.2. Phase II & I (Tabular Information)

6. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Online Pharmacy


7. North America Parkinson’s Disease Therapeutics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.3. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.Parkinson’s Disease Therapeutics Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.1.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.2.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.3.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

8. UK and European Union Parkinson’s Disease Therapeutics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.3. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.Parkinson’s Disease Therapeutics Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.1.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.2.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.3.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.4.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.5.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.6.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

9. Asia Pacific Parkinson’s Disease Therapeutics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.3. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.Parkinson’s Disease Therapeutics Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.1.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.2.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.3.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.4.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.5.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.6.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

10. Latin America Parkinson’s Disease Therapeutics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
10.3. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.Parkinson’s Disease Therapeutics Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.1.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.2.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.3.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

11. Middle East and Africa Parkinson’s Disease Therapeutics Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
11.3. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.Parkinson’s Disease Therapeutics Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.1.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.2.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Parkinson’s Disease Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.3.2. Parkinson’s Disease Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

12. Company Profile
12.1. Abbvie, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Biogen, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Boehringer Ingelheim GmbH
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. F. Hoffman-La Roche
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. GlaxoSmithKline Plc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. H. Lundbeck A/S
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Impax Labs, Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Newron Pharmaceuticals SpA
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Novartis AG
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Orion Corporation
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Teva Pharmaceutical Industries Ltd.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. UCB S.A.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Others
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives